消化性潰瘍治療薬市場：製品タイプ別、潰瘍タイプ別、流通チャネル別、地域別、2025-2033年

消化性潰瘍治療薬市場の世界市場規模は2024年に49億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに62億米ドルに達し、2025年から2033年にかけて2.51%の成長率（CAGR）を示すと予測しています。消化性潰瘍の有病率の増加、特に高齢者人口の増加、侵襲的な手術よりも様々な薬物療法への消費者志向の変化は、市場成長を促進する主な要因のいくつかです。

消化性潰瘍（十二指腸潰瘍）は、胃、小腸、食道下部の粘膜に徐々に開発され、欠陥を誘発する開放性の痛みです。消化性潰瘍は通常、炎症、放射線療法、アスピリンの頻繁な内服や注射、抗炎症剤投与などが原因で起こる。消化性潰瘍を放置すると、中・上半身の激痛、体重減少、内出血、大出血などを引き起こし、入院が必要になることもあります。現在、プロトンポンプ阻害薬（PPI）、H2拮抗薬、抗生物質、カリウムイオン競合型アシッドブロッカー（P-CAB）、制酸剤、潰瘍保護剤など、さまざまな種類の薬剤で治療することができます。これらの薬剤は、体の痛みを軽減し、治癒までの時間を長くし、酸の分泌を最小限に抑え、細菌感染に対する抵抗力を提供し、消化液から胃を保護します。その結果、消化性潰瘍治療薬は、胃炎、胃食道逆流症（GERD）、十二指腸潰瘍の治療のために、ヘルスケア専門家によって広く利用されています。

消化性潰瘍治療薬市場傾向：

消化性潰瘍の有病率の増加、特に高齢者人口の増加が市場成長を牽引する主要因の1つとなっています。さらに、不健康な生活習慣や胃がんの増加により、消化性潰瘍を患う人の数が増加しています。これは、侵襲的な手術よりも様々な消化性潰瘍治療薬に対する消費者の傾向の変化とともに、市場の成長に寄与しています。これに伴い、外科手術に比べ、ステロイド系抗炎症薬は侵襲性が低く、価格も手頃で、出血量を減らしながら回復を早めることができます。さらに、消化性潰瘍治療薬の承認が進んでいることや、薬の製剤化のために政府が製薬会社に投資していることも、市場の成長を支えています。さらに、合併症を克服するための新薬開発のための継続的な臨床試験の実施や、市場における現行薬の効果の低さも影響しています。さらに、費用対効果の高い消化性潰瘍治療薬の利点に関する消費者の意識の高まりと、複数の流通チャネルで容易に入手できることが、市場の成長を後押ししています。また、診断および法医学的操作を行うための人工知能（AI）ベースの病理検査技術の登場も、市場の成長を後押ししています。製品の有効性を高めるための広範な研究開発（R&D）活動や、消化性潰瘍治療用の市販薬（OTC）開発への投資の増加など、その他の要因も市場成長にプラスの影響を与えています。

本レポートで扱う主な質問

• 世界の消化性潰瘍治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
• 世界の消化性潰瘍治療薬市場における促進要因、抑制要因、機会は何か？
• 主要な地域市場とは？
• 最も魅力的な消化性潰瘍治療薬市場はどの国か？
• 製品タイプ別の市場内訳は？
• 潰瘍タイプ別の市場内訳は？
• 流通チャネル別の市場内訳は？
• 世界の消化性潰瘍治療薬市場の競合構造は？
• 世界の消化性潰瘍治療薬市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の消化性潰瘍治療薬市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：製品タイプ別

• プロトンポンプ阻害剤
  • 市場動向
  • 市場予測
• カリウム競合性酸遮断薬（P-CAB）
  • 市場動向
  • 市場予測
• 制酸剤
  • 市場動向
  • 市場予測
• H2拮抗薬
  • 市場動向
  • 市場予測
• 抗生物質
  • 市場動向
  • 市場予測
• 潰瘍保護
  • 市場動向
  • 市場予測

第7章 市場内訳：潰瘍タイプ別

• 胃潰瘍
  • 市場動向
  • 市場予測
• 十二指腸潰瘍
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第8章 市場内訳：流通チャネル別

• 病院薬局
  • 市場動向
  • 市場予測
• 小売薬局
  • 市場動向
  • 市場予測
• オンライン薬局
  • 市場動向
  • 市場予測

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ

第10章 促進要因・抑制要因・機会

• 概要
• 促進要因
• 抑制要因
• 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novitium Pharma LLC
  • Pfizer Inc.
  • PharmaKing Co. Ltd.
  • RedHill Biopharma Ltd
  • Viatris Inc.
  • Yuhan Corporation
  • Zydus Lifesciences Limited

List of Figures

• Figure 1: Global: Peptic Ulcer Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Peptic Ulcer Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Peptic Ulcer Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Peptic Ulcer Drugs Market: Breakup by Product Type (in %), 2024
• Figure 5: Global: Peptic Ulcer Drugs Market: Breakup by Ulcer Type (in %), 2024
• Figure 6: Global: Peptic Ulcer Drugs Market: Breakup by Distribution Channel (in %), 2024
• Figure 7: Global: Peptic Ulcer Drugs Market: Breakup by Region (in %), 2024
• Figure 8: Global: Peptic Ulcer Drugs (Proton Pump Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Peptic Ulcer Drugs (Proton Pump Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Peptic Ulcer Drugs (Potassium-Competitive Acid Blocker (P-CAB)) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Peptic Ulcer Drugs (Potassium-Competitive Acid Blocker (P-CAB)) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Peptic Ulcer Drugs (Antacids) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Peptic Ulcer Drugs (Antacids) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Peptic Ulcer Drugs (H2-Antagonists) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Peptic Ulcer Drugs (H2-Antagonists) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Peptic Ulcer Drugs (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Peptic Ulcer Drugs (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Peptic Ulcer Drugs (Ulcer Protective) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Peptic Ulcer Drugs (Ulcer Protective) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Peptic Ulcer Drugs (Gastric Ulcer) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Peptic Ulcer Drugs (Gastric Ulcer) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Peptic Ulcer Drugs (Duodenal Ulcer) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Peptic Ulcer Drugs (Duodenal Ulcer) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Peptic Ulcer Drugs (Other Ulcer Types) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Peptic Ulcer Drugs (Other Ulcer Types) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Peptic Ulcer Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Peptic Ulcer Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Peptic Ulcer Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Peptic Ulcer Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Global: Peptic Ulcer Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Global: Peptic Ulcer Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: North America: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: North America: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: United States: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: United States: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Canada: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Canada: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Asia-Pacific: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Asia-Pacific: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: China: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: China: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Japan: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Japan: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: India: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: India: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: South Korea: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: South Korea: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Australia: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Australia: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Indonesia: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Indonesia: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Others: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Others: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Europe: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Europe: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Germany: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Germany: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: France: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: France: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: United Kingdom: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: United Kingdom: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Italy: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Italy: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Spain: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Spain: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Russia: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Russia: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Others: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Others: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Latin America: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Latin America: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Brazil: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Brazil: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: Mexico: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: Mexico: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Others: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Others: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 78: Middle East and Africa: Peptic Ulcer Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 79: Middle East and Africa: Peptic Ulcer Drugs Market: Breakup by Country (in %), 2024
• Figure 80: Middle East and Africa: Peptic Ulcer Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 81: Global: Peptic Ulcer Drugs Industry: Drivers, Restraints, and Opportunities
• Figure 82: Global: Peptic Ulcer Drugs Industry: Value Chain Analysis
• Figure 83: Global: Peptic Ulcer Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Peptic Ulcer Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Peptic Ulcer Drugs Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
• Table 3: Global: Peptic Ulcer Drugs Market Forecast: Breakup by Ulcer Type (in Million USD), 2025-2033
• Table 4: Global: Peptic Ulcer Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 5: Global: Peptic Ulcer Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Peptic Ulcer Drugs Market: Competitive Structure
• Table 7: Global: Peptic Ulcer Drugs Market: Key Players

The global peptic ulcer drugs market size reached USD 4.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.2 Billion by 2033, exhibiting a growth rate (CAGR) of 2.51% during 2025-2033. The increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various medications over invasive surgeries represent some of the key factors driving the market growth.

Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives. These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.

Peptic Ulcer Drugs Market Trends:

The increasing prevalence of peptic ulcers, especially amongst the geriatric population, represents one of the key factors driving the market growth. Moreover, unhealthy lifestyle habits and rising instances of stomach cancer, is resulting in the growing number of individuals suffering from peptic ulcers. This, along with the shifting consumer inclination towards various peptic ulcer-curing drugs over invasive surgeries, which, in turn, is contributing to the market growth. In line with this, as compared to surgical procedures, several steroidal anti-inflammatory medications are minimally invasive, more affordable, and enable faster recovery while ensuring reduced blood loss. Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth. The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.

Key Market Segmentation:

Product Type Insights:

• Proton Pump Inhibitors
• Potassium-Competitive Acid Blocker (P-CAB)
• Antacids
• H2-Antagonists
• Antibiotics
• Ulcer protective
• The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the product type. This includes proton pump inhibitors, potassium-competitive acid blocker (P-CAB), antacids, H2-antagonists, antibiotics, and ulcer protective. According to the report, antibiotics represented the largest segment.

Ulcer Type Insights:

• Gastric Ulcer
• Duodenal Ulcer
• Others

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for peptic ulcer drugs. Some of the factors driving the North America peptic ulcer drugs market included the increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various peptic ulcer curing drugs over invasive surgeries and the fueling need for over-the-counter (OTC) medications in the healthcare sector.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global peptic ulcer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• How has the global peptic ulcer drugs market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global peptic ulcer drugs market?
• What are the key regional markets?
• Which countries represent the most attractive peptic ulcer drugs market?
• What is the breakup of the market based on the product type?
• What is the breakup of the market based on the ulcer type?
• What is the breakup of the market based on the distribution channel?
• What is the competitive structure of the global peptic ulcer drugs market?
• Who are the key players/companies in the global peptic ulcer drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Peptic Ulcer Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Proton Pump Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Potassium-Competitive Acid Blocker (P-CAB)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Antacids
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 H2-Antagonists
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Antibiotics
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Ulcer Protective
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Ulcer Type

• 7.1 Gastric Ulcer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Duodenal Ulcer
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AstraZeneca plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Boehringer Ingelheim International GmbH
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Novitium Pharma LLC
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Pfizer Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 PharmaKing Co. Ltd.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 RedHill Biopharma Ltd
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
  • 14.3.8 Viatris Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Yuhan Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Zydus Lifesciences Limited
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.